首页> 美国卫生研究院文献>Nature Public Health Emergency Collection >A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β
【2h】

A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β

机译:选择性药效团设计的合理方法:特异性识别Gsk3β的创新策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We propose a novel cheminformatics approach that combines structure and ligand-based design to identify target-specific pharmacophores with well-defined exclusion ability. Our strategy includes the prediction of selective interactions, developing structure, and knowledge-based selective pharmacophore models, followed by database screening and molecular docking. This unique strategy was employed in addressing the off-target toxicity of Gsk3β and CDKs. The connections of Gsk3β in eukaryotic cell apoptosis and the extensive potency of Gsk3β inhibitors to block cell death have made it a potential drug-discovery target for many grievous human disorders. Gsk3β is phylogenetically very closely related to the CDKs, such as CDK1 and CDK2, which are suggested to be the off-target proteins of Gsk3β inhibitors. Here, we have employed novel computational approaches in designing the ligand candidates that are potentially inhibitory against Gsk3β, with well-defined the exclusion ability to CDKs. A structure-ligand -based selective pharmacophore was modeled. This model was used to retrieve molecules from the zinc database. The hits retrieved were further screened by molecular docking and protein–ligand interaction fingerprints. Based on these results, four molecules were predicted as selective Gsk3β antagonists. It is anticipated that this unique approach can be extended to investigate any protein–ligand specificity.
机译:我们提出了一种新颖的化学信息学方法,该方法结合了结构和基于配体的设计来鉴定具有明确定义的排阻能力的靶标特异性药效基团。我们的策略包括预测选择性相互作用,发展结构和基于知识的选择性药效团模型,然后进行数据库筛选和分子对接。这种独特的策略用于解决Gsk3β和CDK的脱靶毒性。 Gsk3β在真核细胞凋亡中的连接以及Gsk3β抑制剂在阻止细胞死亡方面具有广泛的作用,使其成为许多严重人类疾病的潜在药物发现靶标。 Gsk3β在系统发育上与CDK密切相关,例如CDK1和CDK2,它们被认为是Gsk3β抑制剂的脱靶蛋白。在这里,我们采用了新颖的计算方法来设计潜在抑制Gsk3β的配体候选物,并明确定义了对CDKs的排斥能力。对基于结构配体的选择性药效团进行了建模。该模型用于从锌数据库中检索分子。通过分子对接和蛋白质-配体相互作用指纹进一步筛选检索到的命中。根据这些结果,预测有四个分子是选择性的Gsk3β拮抗剂。可以预期,这种独特的方法可以扩展到研究任何蛋白质-配体特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号